Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10216374

[Valacyclovir].

M Biernat-Sudolska
View original source ↗Export metadata ↓

Abstract

The paper concerns the new antiviral compound Valaciclovir--prodrug of Aciclovir, which is now in clinical studies. Antiviral activity, pharmacokinetic properties observed in animal studies, as well in immunocompetent and immunosuppressed patients are presented. Its clinical efficacy in herpes virus infection is also discussed.

Explore related subjects

AcyclovirAnimalsAntiviral AgentsHerpesviridae InfectionsHumansValacyclovirValineJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Biernat-Sudolska. 1998. [Valacyclovir].. https://pubmed.ncbi.nlm.nih.gov/10216374/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation.

Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed among 196 allogeneic stem cell transplant recipients within a 29-month period. Recipients of unrelated stem cell transplants were at higher risk. All patients received foscarnet; 8 subsequently received cidofovir. Strains were initially foscarnet-resistant in 3 patients and secondarily so in 4 patients. In vitro resistance to acyclovir or foscarnet was associated with clinical failure of these drugs; however, in vitro susceptibility to foscarnet was associated with complete response in only 5 of 7 patients. No strain from any of the 7 patients was resistant in vitro to cidofovir; however, only 3 of 7 patients achieved complete response. Therefore, acyclovir- and/or foscarnet-resistant HSV-1 infections after allogeneic stem cell transplantation have become a concern; current strategies need to be reassessed and new strategies must be evaluated in this setting.

Acyclovir↗
PubMed2000

Early diagnosis of zoster sine herpete and antiviral therapy for the treatment of facial palsy.

The effect of antiviral agents on recovery from facial palsy in patients with zoster sine herpete (ZSH; varicella zoster virus reactivation without zoster) has not been evaluated because ZSH is difficult to diagnose early after onset. In this study, all 13 patients who received acyclovir-prednisone treatment within 7 days of onset, as confirmed by a positive PCR result, showed complete recovery. PCR-based early diagnosis of ZSH and antiviral therapy elicited an excellent outcome for recovery from facial palsy due to ZSH.

Acyclovir↗